Jacob L. Goldberg

Jacob L. Goldberg

Auto-generated profile, based on publicly available information

Jacob L. Goldberg

Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, New York, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in World Neurosurgery
Verified
Journal Article
Closed access
SKSertac Kirnaz
Sertac Kirnaz
CCCharisse Capadona
Charisse Capadona
TWTaylor Wong
Taylor Wong
JGJacob L. Goldberg
Jacob L. Goldberg
BMBranden Medary
Branden Medary
RHRoger Härtl
Roger Härtl

10 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FNFariba Navid
Fariba Navid
PSPaul M. Sondel
Paul M. Sondel
RBRaymond Barfield
Raymond Barfield
BSBarry L. Shulkin
Barry L. Shulkin
RKRobert A. Kaufman
Robert A. Kaufman
VSVictor M. Santana
Victor M. Santana
Purpose: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related toxicities that may be partially mediated by complement activation. We report the results of a phase I trial to determine the maximum-tolerated dose (MTD), safety profile, and pharmacokinetics of hu14.18K322A, a humanized anti-GD2 mAb with a single point mutation (K322A) that reduces complement-dependent lysis.Patients and Methods: Eligible patients with refractory or recurrent neuroblastoma received escalating doses of hu14.18K322A ranging from 2 to 70 mg/m2per day for 4 consecutive days every 28 days (one course).Results: Thirty-eight patients (23 males; median age, 7.2 years) received a median of two courses (range, one to 15). Dose-limiting grade 3 or 4 toxicities occurred in four of 36 evaluable patients and were characterized by cough, asthenia, sensory neuropathy, anorexia, serum sickness, and hypertensive encephalopathy. The most common non–dose-limiting grade 3 or 4 toxicities during course one were pain (68%) and fever (21%). Six of 31 patients evaluable for response by iodine-123 metaiodobenzylguanidine score had objective responses (four complete responses; two partial responses). The first-course pharmacokinetics of hu14.18K322A were best described by a two-compartment linear model. Median hu14.18K322A α (initial phase) and β (terminal phase) half-lives were 1.74 and 21.1 days, respectively.Conclusion: The MTD, and recommended phase II dose, of hu14.18K322A is 60 mg/m2per day for 4 days. Adverse effects, predominately pain, were manageable and improved with subsequent courses.

3 August 2016 in Immunotherapy
Verified
Journal Article
Closed access
ZHZulmarie Perez Horta
Zulmarie Perez Horta
JGJacob L Goldberg
Jacob L Goldberg
PSPaul Sondel
Paul Sondel
Tumor-specific monoclonal antibodies (mAbs) have demonstrated efficacy in the clinic, becoming an important approach for cancer immunotherapy. Due to its limited expression on normal tissue, the GD2 disialogangloside expressed on neuroblastoma cells is an excellent candidate for mAb therapy. In 2015, dinutuximab (an anti-GD2 mAb) was approved by the US FDA and is currently used in a combination immunotherapeutic regimen for the treatment of children with high-risk neuroblastoma. Here, we review the extensive preclinical and clinical development of anti-GD2 mAbs and the different mechanisms by which they mediate tumor cell killing. In addition, we discuss different mAb-based strategies that capitalize on the targeting ability of anti-GD2 mAbs to potentially deliver, as monotherapy, or in combination with other treatments, improved antitumor efficacy.

8 November 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
DADoralina L. Anghelescu
Doralina L. Anghelescu
JGJacob L. Goldberg
Jacob L. Goldberg
LFLane G. Faughnan
Lane G. Faughnan
JWJianrong Wu
Jianrong Wu
SMShenghua Mao
Shenghua Mao
FNFariba Navid
Fariba Navid

15 June 2022 in World Neurosurgery
Verified
Journal Article
Closed access
JGJacob L. Goldberg
Jacob L. Goldberg
RHRoger Härtl
Roger Härtl
EEEric Elowitz
Eric Elowitz

1 August 2015 in Seminars in Oncology
Verified
Journal Article
Open access
JGJacob L. Goldberg
Jacob L. Goldberg
PSPaul Sondel
Paul Sondel
Given recent technological advances and advances in our understanding of cancer, immunotherapy of cancer is being used with clear clinical benefit. The immunosuppression accompanying cancer itself, as well as with current cancer treatment with radiation or chemotherapy, impairs adaptive immune effectors to a greater extent than innate effector cells. In addition to being less suppressed, innate immune cells are capable of being enhanced via immune-stimulatory regimens. Most strategies being investigated to promote innate immune responses against cancer do not require complex, patient-specific, ex vivo cellular or molecular creation of therapeutic agents; thus they can, generally, be used as “off the shelf” therapeutics that could be administered by most cancer clinics. Successful applications of innate immunotherapy in the clinic have effectively targeted components of the innate immune response. Preclinical data demonstrate how initiation of innate immune responses can lead to subsequent adaptive long-term cancer immunity. We hypothesize that integration of innate immune activation strategies into combination therapies for cancer treatment will lead to more effective and long-term clinical benefit.